| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/CIRCGENETICS.108.818062 |
| P698 | PubMed publication ID | 20031582 |
| P50 | author | David A Hinds | Q37391803 |
| John F Thompson | Q39892280 | ||
| David R. Cox | Q64014869 | ||
| John J. P. Kastelein | Q110410211 | ||
| P2093 | author name string | G Kees Hovingh | |
| Linda S Wood | |||
| Sara A Paciga | |||
| Craig L Hyde | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | whole genome sequencing | Q2068526 |
| statin therapy | Q62562875 | ||
| P304 | page(s) | 173-181 | |
| P577 | publication date | 2009-02-12 | |
| P1433 | published in | Circulation: Cardiovascular Genetics | Q15816430 |
| P1476 | title | Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort | |
| P478 | volume | 2 |
| Q90065644 | A gene-diet interaction-based score predicts response to dietary fat in the Women's Health Initiative |
| Q40817564 | A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering |
| Q51272834 | A genetic risk score is significantly associated with statin therapy response in the elderly population. |
| Q35511685 | A multivariate genome-wide association analysis of 10 LDL subfractions, and their response to statin treatment, in 1868 Caucasians |
| Q92350874 | A phenome-wide association study (PheWAS) in the Population Architecture using Genomics and Epidemiology (PAGE) study reveals potential pleiotropy in African Americans |
| Q37908891 | A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application? |
| Q41853330 | ALTERED BLOOD SPHINGOLIPIDOMICS AND ELEVATED PLASMA INFLAMMATORY CYTOKINES IN COMBAT VETERANS WITH POST-TRAUMATIC STRESS DISORDER |
| Q39622951 | Added value of pharmacogenetic testing in predicting statin response: results from the REGRESS trial |
| Q34157965 | Ancestry and other genetic associations with plasma PCSK9 response to simvastatin |
| Q24294486 | Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation |
| Q34013483 | Apolipoprotein E Genotype and Cardiovascular Diseases in the Elderly |
| Q34809332 | Apolipoprotein E epsilon-4 polymorphism is associated with younger age at referral to a lipidology clinic and a poorer response to lipid-lowering therapy. |
| Q35639536 | Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin |
| Q42291683 | Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects |
| Q34997022 | Association of hypertension drug target genes with blood pressure and hypertension in 86,588 individuals |
| Q35933626 | CYP3A5 genotyping for assessing the efficacy of treatment with simvastatin and atorvastatin |
| Q35447163 | Cardiovascular pharmacogenomics |
| Q37620582 | Characterization of statin dose response in electronic medical records |
| Q26849254 | Clinical application of cardiovascular pharmacogenetics |
| Q34016327 | Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin |
| Q27345037 | Coordinately regulated alternative splicing of genes involved in cholesterol biosynthesis and uptake |
| Q37193537 | Differential Lipid Response to Statins Is Associated With Variants in the BUD13-APOA5 Gene Region |
| Q35380116 | Disruption of the murine procollagen C-proteinase enhancer 2 gene causes accumulation of pro-apoA-I and increased HDL levels |
| Q37873935 | Effect of apolipoprotein E polymorphism on statin-induced decreases in plasma lipids and cardiovascular events |
| Q37286031 | Electronic medical records as a tool in clinical pharmacology: opportunities and challenges |
| Q27026358 | Evaluation of the effect of genetic variation on the relationship between statins, cardiovascular disease and cancer |
| Q38155218 | Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin |
| Q38098452 | Expanding role of pharmacogenomics in the management of cardiovascular disorders |
| Q51368587 | Gender, but not CYP7A1 or SLCO1B1 polymorphism, affects the fasting plasma concentrations of bile acids in human beings. |
| Q41199627 | Gene expression profiles associated with acute myocardial infarction and risk of cardiovascular death |
| Q91736525 | Genetic contribution to lipid target achievement with statin therapy: a prospective study |
| Q36301394 | Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI |
| Q38167710 | Genetics and personalized medicine--a role in statin therapy? |
| Q37592123 | Genetics of lipid disorders |
| Q21142620 | Genome-wide association of lipid-lowering response to statins in combined study populations |
| Q34415006 | Genome-wide association studies in pharmacogenomics: successes and lessons |
| Q24594382 | Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a) |
| Q28729086 | Genome-wide study of gene variants associated with differential cardiovascular event reduction by pravastatin therapy |
| Q40499193 | HMGCR rs17671591 SNP Determines Lower Plasma LDL-C after Atorvastatin Therapy in Chilean Individuals |
| Q36730132 | Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study |
| Q37961088 | Integrative genomics strategies to elucidate the complexity of drug response |
| Q38924930 | Laboratory Medicine in the Clinical Decision Support for Treatment of Hypercholesterolemia: Pharmacogenetics of Statins |
| Q55361379 | Lack of genetic support for shared aetiology of Coronary Artery Disease and Late-onset Alzheimer's disease. |
| Q38129422 | Lipid-lowing pharmacogenomics in Chinese patients |
| Q34348337 | Mapping genes that predict treatment outcome in admixed populations |
| Q37854349 | Medical DNA sequencing |
| Q36854531 | Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents |
| Q34994907 | PharmGKB: very important pharmacogene--HMGCR. |
| Q34680467 | Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins |
| Q34453666 | Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins |
| Q36974672 | Pharmacogenetics and cardiovascular disease--implications for personalized medicine |
| Q45337198 | Pharmacogenetics in cardiovascular disease: the challenge of moving from promise to realization: concepts discussed at the Canadian Network and Centre for Trials Internationally Network Conference (CANNeCTIN), June 2009. |
| Q38094070 | Pharmacogenetics in cardiovascular disorders: an update on the principal drugs. |
| Q38780996 | Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine? |
| Q38010751 | Pharmacogenetics of statins: achievements, whole-genome analyses and future perspectives |
| Q35158967 | Pharmacogenomic Biomarkers for the Prediction of Statin Efficacy and Safety |
| Q26997380 | Pharmacogenomics and cardiovascular disease |
| Q38112823 | Pharmacogenomics of lipid-lowering therapies |
| Q28079822 | Pharmacogenomics of statins: understanding susceptibility to adverse effects |
| Q38203774 | Pharmacogenomics, lipid disorders, and treatment options |
| Q34066977 | Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol? |
| Q56545969 | Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study |
| Q51059622 | Predicting individual responses to pravastatin using a physiologically based kinetic model for plasma cholesterol concentrations. |
| Q34269364 | Prediction of LDL cholesterol response to statin using transcriptomic and genetic variation |
| Q38109960 | Proprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: hepatic and extra hepatic functions |
| Q34732931 | Quality control procedures for genome-wide association studies |
| Q28485187 | RHOA is a modulator of the cholesterol-lowering effects of statin |
| Q39880462 | Regulation of apoAI processing by procollagen C-proteinase enhancer-2 and bone morphogenetic protein-1. |
| Q33948919 | Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with [...] |
| Q38670109 | Seventeen years of statin pharmacogenetics: a systematic review |
| Q33690357 | Statin pharmacogenomics: pursuing biomarkers for predicting clinical outcomes |
| Q37227150 | Statin-induced expression change of INSIG1 in lymphoblastoid cell lines correlates with plasma triglyceride statin response in a sex-specific manner. |
| Q38868416 | Statins and Their Effect on PCSK9-Impact and Clinical Relevance |
| Q35047843 | Strategic approaches to unraveling genetic causes of cardiovascular diseases |
| Q36485405 | THE CHALLENGES IN USING ELECTRONIC HEALTH RECORDS FOR PHARMACOGENOMICS AND PRECISION MEDICINE RESEARCH |
| Q38017196 | The biology and therapeutic targeting of the proprotein convertases |
| Q46376996 | The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy |
| Q38735798 | The effects of rosuvastatin on lipid-lowering, inflammatory, antioxidant and fibrinolytics blood biomarkers are influenced by Val16Ala superoxide dismutase manganese-dependent gene polymorphism. |
| Q92862394 | The impact of adjusting for baseline in pharmacogenomic genome-wide association studies of quantitative change |
| Q37771903 | The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis |
| Q37652284 | The role of HMGCR alternative splicing in statin efficacy |
| Q37880856 | The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications |
| Q38130427 | To replicate or not to replicate: the case of pharmacogenetic studies: Establishing validity of pharmacogenomic findings: from replication to triangulation. |
| Q35645239 | Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials |
Search more.